C4 Therapeutics(US:CCCC) Globenewswire·2025-08-07 11:00Core Insights - C4 Therapeutics, Inc. reported that cemsidomide, an investigational drug for multiple myeloma, has shown an overall response rate (ORR) of 40% at the 75 µg dose level and 50% at the 100 µg dose level in Phase 1 trials [1][7] - The company is on track to initiate registrational development for cemsidomide in early 2026 following a productive Type C meeting with the FDA [1][3] - Financial results for Q2 2025 showed total revenue of $6.5 million, a decrease from $12.0 million in Q2 2024, primarily due to a milestone payment received in the previous year [9][10] Cemsidomide Development - C4 Therapeutics completed enrollment in ongoing Phase 1 trials for cemsidomide in multiple myeloma and non-Hodgkin's lymphoma, with data to be presented at the International Myeloma Society Annual Meeting in September 2025 [3][7] - The next phase of development will evaluate cemsidomide in combination with dexamethasone and a B-cell maturation antigen bispecific T-cell engager for multiple myeloma treatment [7] Financial Performance - R&D expenses for Q2 2025 were $26.2 million, up from $23.8 million in Q2 2024, mainly due to clinical trial costs for cemsidomide [10] - General and administrative expenses decreased to $8.8 million in Q2 2025 from $9.7 million in Q2 2024 [11] - The net loss for Q2 2025 was $26.0 million, compared to $17.7 million in Q2 2024, with a net loss per share of $0.37 [11][12] Cash Position - As of June 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $223.0 million, down from $267.3 million at the end of 2024 [12][20] - The current cash position is expected to fund operations through mid-2027 [12]